Stated-preference study to examine the economic value of benefits of avoiding selected adverse human health outcomes due to exposure to chemicals in the European Union: Part III: Carcinogens
Abstract
Stated-preference study to examine the economic value of benefits of avoiding selected adverse human health outcomes due to exposure to chemicals in the European Union: Part III: Carcinogens The primary objective of this stated-preference study was to estimate willingness to pay to avoid selected adverse human health outcomes due to exposure to chemicals in the European Union and to derive representative EU-wide benefit estimates reference values. The results are intended for use by ECHA and other bodies when carrying out socio-economic analyses or health impact assessments in connection to REACH Regulation.
This report focuses on health outcomes linked to carcinogens, particularly to cancer risks. Each health outcome that is valued in this study was selected based on a comprehensive literature review, consultations with epidemiologists and medical experts and in close cooperation with ECHA.